


EXAMINER'S AMENDMENT

Claim Summary

1 – 11 (canceled)

¹ ~~12.~~ (currently amended) A compound of the formula (I):



wherein

R¹ is alkyl having 1 to 4 carbons or halogen;

R² is alkyl having 1 to 4 carbons;

R³ is hydrogen or hydroxy; and

A is oxygen or C(R⁴)(R⁵);

R⁴ is alkyl having 1 to 4 carbons or hydrogen; and

R⁵ is alkyl having 1 to 4 carbons or hydroxy;

or a pharmaceutically acceptable salt thereof.

² ~~13.~~ (previously presented) The compound of claim 12, wherein R¹ is halogen.

³ ~~14.~~ (previously presented) The compound of claim 12, wherein R² is alkyl having 1 to 2 carbons.

⁴ ~~15.~~ (previously presented) The compound of claim 13, wherein R² is alkyl having 1 to 2 carbons.

5 16. (previously presented) The compound of claim ¹~~12~~, wherein R³ is hydroxy.

6 17. (previously presented) The compound of claim ²~~13~~, wherein R³ is hydroxy.

7 18. (previously presented) The compound of claim ⁴~~15~~, wherein R³ is hydroxy.

19. (canceled)

20. (canceled)

21. (canceled)

8 22. (currently amended) A compound selected from:

5-chloro-N-({1-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]piperidin-4-yl}methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihdropyridine-3-carboxamide;

5-chloro-6-ethyl-N-({1-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]piperidin-4-yl}methyl)-1-isopropyl-2-oxo-1,2-dihdropyridine-3-carboxamide;

N-({1-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5,6-dimethyl-2-oxo-1,2-dihdropyridine-3-carboxamide;

5-bromo-N-({1-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]piperidin-4-yl}methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihdropyridine-3-carboxamide; or

5-fluoro-N-({1-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]piperidin-4-yl}methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihdropyridine-3-carboxamide;

5-fluoro-6-((1-(4-hydroxytetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihdropyridine-3-carboxamide;

5-chloro-N-((1-(cyclohexyl)methyl)piperidin-4-yl)methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihdropyridine-3-carboxamide; or

5-chloro-N-((1-((1-hydroxycyclohexyl)methyl)piperidin-4-yl)methyl)-1-isopropyl-6-methyl-2-oxo-1,2-dihdropyridine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

9 23. (previously presented) A pharmaceutical composition comprising a compound of claim ¹~~12~~ or a pharmaceutically acceptable salt thereof together with at least one pharmaceutically acceptable carrier.

24. (canceled)

/CC/
11/19/09

¹⁰
~~25.~~ (previously presented) A method for treating gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, ^{and} ~~gastroesophageal~~ disease, nausea, ~~central nervous system disease, Alzheimer's disease, cognitive disorder,~~ emesis, migraine, neurological disease, pain, diabetes, apnoea syndrome, cardiac failure, or heart arrhythmia comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim ~~12~~¹ or a pharmaceutically acceptable salt thereof.

¹¹
~~26.~~ (previously presented) A method for treating gastroesophageal reflux disease comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim ~~12~~¹ or a pharmaceutically acceptable salt thereof.